SpaceX vs Rocket Lab: What's the Better Buy Right Now?

SpaceX is described as a newly public stock with an estimated $2 trillion market cap and more than $4 billion in Q1 losses, while Rocket Lab is valued at about $60 billion with trailing 12-month losses of $183 million. Rocket Lab posted quarterly revenue above $200 million, up nearly 64% year over year, and has secured more than $1.3 billion in U.S. Space Development Agency contracts ahead of its planned Neutron rocket launch later this year. The piece is largely comparative and opinion-driven, concluding that SpaceX is the preferred buy despite its premium valuation.

Analysis

The market is effectively pricing a call option on a private-space platform layer, but the second-order effect is that capital is likely to keep flowing into the entire launch/infrastructure complex rather than just the headline name. That typically favors the smaller public pure-plays with nearer-term catalysts because they offer cleaner beta to “space re-rating” without the same absolute valuation overhang. In that setup, the main loser is any incumbent aerospace prime whose growth narrative gets crowded out by faster-moving, narrative-driven capital rotation.

The bigger risk is not operational execution alone; it is the duration mismatch between hype and cash generation. If the next 1-2 launches or product milestones slip by even one quarter, the market can quickly re-anchor on dilution risk and financing needs, which matters much more for the smaller name. The most fragile period is the next 3-6 months, when sentiment can stay elevated but fundamentals remain too thin to justify the multiple unless there is a clean catalyst.

A more interesting contrarian read is that the public market may be overestimating the benefit to the “winner” while underestimating the spillover to suppliers, launch-service adjacencies, and defense-linked contractors. If private-market enthusiasm sustains, the trade may be in the picks-and-shovels layer: entities with existing government relationships, backlog visibility, and less binary execution risk. That is a better way to express the theme than paying peak multiples for an asset where good news is already embedded.

Near term, the setup is most vulnerable to any pullback in retail appetite for long-duration growth stories; these names trade more like momentum assets than fundamentals. Conversely, a successful near-term technical milestone could trigger a sharp repricing because short interest and scarce supply tend to amplify upside in speculative niches. The asymmetry is attractive only if sized small and paired with a defined exit around catalyst completion.

Key Decisions for Investors

• Long RKLB into Neutron launch window over the next 1-3 months, but treat it as a catalyst trade only; risk/reward is attractive if launch is clean, but stop-loss discipline is essential because a slip can compress the multiple fast.
• Use a pair trade: long defense-linked space infrastructure exposure, short a basket of the highest-multiple speculative space names for 3-6 months; this captures thematic inflows while hedging execution and sentiment risk.
• Buy short-dated call spreads on RKLB only if launch timing is confirmed; structure it as defined-risk upside exposure with max loss capped, since implied volatility should remain elevated.
• Avoid chasing the headline private-market leader at current valuation; from a public-market perspective the best risk/reward is in the secondary beneficiaries rather than the most expensive narrative asset.
• If retail enthusiasm fades over the next 2-4 weeks, rotate out of momentum exposure and into backlog-rich aerospace/defense names; the downside in speculative names can be abrupt once the flow turns.